Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

37.85
+1.032.80%
Pre-market: 38.260.4076+1.08%06:43 EDT
Volume:2.07M
Turnover:78.79M
Market Cap:5.09B
PE:-10.87
High:38.92
Open:36.99
Low:36.70
Close:36.82
52wk High:49.70
52wk Low:8.77
Shares:134.37M
Float Shares:129.77M
Volume Ratio:0.64
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4823
EPS(LYR):-2.0600
ROE:-64.09%
ROA:-20.64%
PB:5.54
PE(LYR):-18.37

Loading ...

Definium Therapeutics Issues Inducement Stock Options to New Hires

TIPRANKS
·
11 hours ago

Definium Therapeutics Logs Third Positive Phase 3 Readout for DT120 in Anxiety

TIPRANKS
·
11 hours ago

China's Lepu Biopharma H1 Revenue Rises 12.1% on Higher Drug Sales

Reuters
·
Yesterday

Stifel Nicolaus Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)

TIPRANKS
·
Yesterday

Definium Therapeutics is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Sep 15

U.S. Research Roundup-Eli Lilly, McDonald's, Welltower

Reuters
·
Sep 15

UK's ImmuPharma Interim Net Loss Widens on Derivative Finance Loss

Reuters
·
Sep 15

UK's ValiRx Half-Year Loss Narrows, Cash Position Improves

Reuters
·
Sep 15

Kestra Medical Technologies Q1 Revenue Beats Estimates, Raises FY Revenue Outlook

Reuters
·
Sep 15

Experts Urge FDA to Set Clear Safety and Access Standards for Psychedelic Drugs

Reuters
·
Sep 15

Definium Therapeutics price target raised to $91 from $75 at BofA

TIPRANKS
·
Sep 15

FDA to Hold Public Hearing on Psychedelic Drugs as Trump-Driven Push Gathers Pace

Reuters
·
Sep 15

Analysts’ Top Healthcare Picks: Corbus Pharmaceuticals (CRBP), Definium Therapeutics (DFTX)

TIPRANKS
·
Sep 15

Top Midday Stories: No OpenAI IPO in 2026, Altman Reportedly Says; Nvidia, Palantir Said to Restrict AI Usage Over Customer Data Fears

MT Newswires Live
·
Sep 14

First Marijuana, Then Peptides. Why Psychedelics are Wall Street's Next Big Trip.

Dow Jones
·
Sep 14

Definium Therapeutics Inc : Leerink Partners Raises Target Price to $70 from $52

THOMSON REUTERS
·
Sep 14

Definium Therapeutics Price Target Maintained with a $66.00/Share by Needham

Dow Jones
·
Sep 14

Definium Therapeutics Shares Gain After Reporting Positive Results in Anxiety Study

Dow Jones
·
Sep 14

Definium Therapeutics Shares Jump 20% Premarket After Co's Lsd-Based Drug Lowers Anxiety in Second Successful Late-Stage Study

THOMSON REUTERS
·
Sep 14

S&P 500 Futures Decline in Premarket Trading; Definium Therapeutics, Primo Brands Lead

Dow Jones
·
Sep 14